Trial Outcomes & Findings for Cefdinir Capsules 300 mg, Non-fasting (NCT NCT00834535)
NCT ID: NCT00834535
Last Updated: 2024-08-20
Results Overview
Bioequivalence based on Cmax.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
32 participants
Primary outcome timeframe
Blood samples collected over a 14 hour period.
Results posted on
2024-08-20
Participant Flow
Participant milestones
| Measure |
Cefdinir (Test) First
300 mg Cefdinir Capsules test product dosed in first period followed by 300 mg Omnicef® Capsules reference product dosed in the second period.
|
Omnicef® (Reference) First
300 mg Omnicef® Capsules reference product dosed in first period followed by 300 mg Cefdinir Capsules test product dosed in the second period.
|
|---|---|---|
|
First Intervention
STARTED
|
16
|
16
|
|
First Intervention
COMPLETED
|
16
|
16
|
|
First Intervention
NOT COMPLETED
|
0
|
0
|
|
Washout of 7 Days
STARTED
|
16
|
16
|
|
Washout of 7 Days
COMPLETED
|
16
|
16
|
|
Washout of 7 Days
NOT COMPLETED
|
0
|
0
|
|
Second Intervention
STARTED
|
16
|
16
|
|
Second Intervention
COMPLETED
|
16
|
16
|
|
Second Intervention
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Cefdinir Capsules 300 mg, Non-fasting
Baseline characteristics by cohort
| Measure |
Cefdinir (Test) First
n=16 Participants
300 mg Cefdinir Capsules test product dosed in first period followed by 300 mg Omnicef® Capsules reference product dosed in the second period.
|
Omnicef® (Reference) First
n=16 Participants
300 mg Omnicef® Capsules reference product dosed in first period followed by 300 mg Cefdinir Capsules test product dosed in the second period.
|
Total
n=32 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
16 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
13 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
19 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White
|
16 participants
n=5 Participants
|
16 participants
n=7 Participants
|
32 participants
n=5 Participants
|
|
Region of Enrollment
United States
|
16 participants
n=5 Participants
|
16 participants
n=7 Participants
|
32 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Blood samples collected over a 14 hour period.Population: All participants that completed the study had their samples analyzed.
Bioequivalence based on Cmax.
Outcome measures
| Measure |
Cefdinir (Test)
n=32 Participants
300 mg Cefdinir Capsules test product dosed in either period.
|
Omnicef® (Reference)
n=32 Participants
300 mg Omnicef® Capsules reference product dosed in either period.
|
|---|---|---|
|
Cmax (Maximum Observed Concentration)
|
2081.37 ng/mL
Standard Deviation 537.12
|
2045.43 ng/mL
Standard Deviation 481.25
|
PRIMARY outcome
Timeframe: Blood samples collected over a 14 hour period.Population: All participants that completed the study had their samples analyzed.
Bioequivalence based on AUC0-t.
Outcome measures
| Measure |
Cefdinir (Test)
n=32 Participants
300 mg Cefdinir Capsules test product dosed in either period.
|
Omnicef® (Reference)
n=32 Participants
300 mg Omnicef® Capsules reference product dosed in either period.
|
|---|---|---|
|
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
|
10700.97 ng*h/mL
Standard Deviation 2328.12
|
11121.51 ng*h/mL
Standard Deviation 2215.78
|
PRIMARY outcome
Timeframe: Blood samples collected over a 14 hour period.Population: All participants that completed the study had their samples analyzed.
Bioequivalence based on AUC0-inf.
Outcome measures
| Measure |
Cefdinir (Test)
n=32 Participants
300 mg Cefdinir Capsules test product dosed in either period.
|
Omnicef® (Reference)
n=32 Participants
300 mg Omnicef® Capsules reference product dosed in either period.
|
|---|---|---|
|
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
|
11219.51 ng*h/mL
Standard Deviation 2304.28
|
11560.85 ng*h/mL
Standard Deviation 2237.52
|
Adverse Events
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The Principal Investigator is not permitted to discuss or publish trial results.
- Publication restrictions are in place
Restriction type: OTHER